Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Carrie C, et al. Among authors: dubray bm. Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16. Lancet Oncol. 2019. PMID: 31629656 Clinical Trial.
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S. Carrie C, et al. Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6. Lancet Oncol. 2016. PMID: 27160475 Clinical Trial.
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
Beckendorf V, Guérif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P. Beckendorf V, et al. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1056-65. doi: 10.1016/j.ijrobp.2004.05.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519775 Clinical Trial.
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.
Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P. Beckendorf V, et al. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63. doi: 10.1016/j.ijrobp.2010.03.049. Epub 2010 Dec 14. Int J Radiat Oncol Biol Phys. 2011. PMID: 21147514 Clinical Trial.
Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C, Kieffer V, Figarella-Branger D, Masliah-Planchon J, Bolle S, Bernier V, Laprie A, Supiot S, Leseur J, Habrand JL, Alapetite C, Kerr C, Dufour C, Claude L, Chapet S, Huchet A, Bondiau PY, Escande A, Truc G, Nguyen TD, Pasteuris C, Vigneron C, Muracciole X, Bourdeaut F, Appay R, Dubray B, Colin C, Ferlay C, Dussart S, Chabaud S, Padovani L; French Group of Pediatric Radiotherapy (GFRP); French Society of Pediatric Cancers (SFCE). Carrie C, et al. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1204-1217. doi: 10.1016/j.ijrobp.2020.07.2324. Epub 2020 Aug 6. Int J Radiat Oncol Biol Phys. 2020. PMID: 32768563
Random forests to predict rectal toxicity following prostate cancer radiation therapy.
Ospina JD, Zhu J, Chira C, Bossi A, Delobel JB, Beckendorf V, Dubray B, Lagrange JL, Correa JC, Simon A, Acosta O, de Crevoisier R. Ospina JD, et al. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1024-1031. doi: 10.1016/j.ijrobp.2014.04.027. Epub 2014 Jul 8. Int J Radiat Oncol Biol Phys. 2014. PMID: 25035205 Clinical Trial.
Nomograms to predict late urinary toxicity after prostate cancer radiotherapy.
Mathieu R, Arango JD, Beckendorf V, Delobel JB, Messai T, Chira C, Bossi A, Le Prisé E, Guerif S, Simon JM, Dubray B, Zhu J, Lagrange JL, Pommier P, Gnep K, Acosta O, De Crevoisier R. Mathieu R, et al. World J Urol. 2014 Jun;32(3):743-51. doi: 10.1007/s00345-013-1146-8. Epub 2013 Aug 29. World J Urol. 2014. PMID: 23990073 Free article.
[Preliminary results of the assessment of intensity modulated radiotherapy (IMRT) for prostatic and head and neck tumors (STIC 2001)].
Marchal C, Lapeyre M, Beckendorf V, Aletti P, Haslé E, Dubois JB, Maingon P, Bensadoun RJ, Le Prise E, Lartigau E, Carrie C, Dubray B, Marchesi V, Ailleres N, Naudy S, Marcie S, Manens JP, Mazurier J, Ginestet C, Chauvin F, Pommier P, Gerard JP, Carrere MO. Marchal C, et al. Cancer Radiother. 2004 Nov;8 Suppl 1:S121-7. Cancer Radiother. 2004. PMID: 15679257 French.
Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S, Marchesi V, Vieillard MH, Perrier L, Lisbona A, Leheurteur M, Tredaniel J, Culine S, Dubray B, Bonnet N, Asselain B, Salleron J, Faivre JC. Thureau S, et al. BMC Cancer. 2021 Feb 4;21(1):117. doi: 10.1186/s12885-021-07828-2. BMC Cancer. 2021. PMID: 33541288 Free PMC article.
Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].
Vera P, Mihailescu SD, Lequesne J, Modzelewski R, Bohn P, Hapdey S, Pépin LF, Dubray B, Chaumet-Riffaud P, Decazes P, Thureau S; all investigators of RTEP5 study (list in annexe). Vera P, et al. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1448-1456. doi: 10.1007/s00259-019-04285-9. Epub 2019 Mar 13. Eur J Nucl Med Mol Imaging. 2019. PMID: 30868230 Clinical Trial.
120 results